Illumina Inc ILMN:NASDAQ

Last Price$324.72NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$316.49 (1)
Ask (Size)$324.72 (1)
Day Low / HighN/A - N/A
Volume1.1 M
 

View Biotechnology IndustryPeer Comparison as of 01/17/2020

 

Illumina Inc ( NASDAQ )

Price: $324.72
Change: -1.24 (0.38%)
Volume: 1.1 M
4:00PM ET 1/17/2020
 
 

Biogen Inc ( NASDAQ )

Price: $285.50
Change: -0.64 (0.22%)
Volume: 1.8 M
4:00PM ET 1/17/2020
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $385.94
Change: +0.37 (0.10%)
Volume: 862.8 K
4:00PM ET 1/17/2020
 
 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $235.83
Change: +0.33 (0.14%)
Volume: 1.6 M
4:00PM ET 1/17/2020
 
 

Agilent Technologies Inc ( NYSE )

Price: $90.12
Change: +0.66 (0.74%)
Volume: 3.7 M
6:30PM ET 1/17/2020
 

Read more news Recent News

Illumina Guidance for 2020 Lags Estimates, Partners Roche For Genomic Testing
2:46PM ET 1/13/2020 MT Newswires

Illumina (ILMN) on Monday provided earnings and revenue guidance for 2020 that came in lower than expected, sending shares of the diagnostics company down...

Illumina Files Two Additional Patent Infringement Suits Against BGI
9:18AM ET 1/10/2020 MT Newswires

Illumina (ILMN) said pre-market Friday it filed two additional patent infringement suits against BGI in Sweden and the UK. The additional lawsuits relate...

Analyst Actions: Wells Fargo Initiates Coverage on Illumina With Underweight Rating, $300 Price Target
11:02AM ET 1/08/2020 MT Newswires

Illumina's (ILMN) average rating among analysts is a buy, with an average price target of $338. Price: 329.06, Change: -0.63, Percent Change: -0.19 ...

Analyst Actions: Citigroup Initiates Coverage on Illumina With Buy Rating, $385 Price Target
7:38AM ET 1/07/2020 MT Newswires

Illumina's (ILMN) average rating among analysts is a buy, with an average price target of $333. Price: 325.53, Change: +2.80, Percent Change: +0.87 ...

Company Profile

Business DescriptionIllumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA. View company web site for more details
Address5200 Illumina Way
San Diego, California 92122
Phone+1.858.202.4500
Number of Employees7,300
Recent SEC Filing01/16/2020SC 13G/A
President, Chief Executive Officer & DirectorFrancis A. deSouza
Senior Vice President-Global Quality & OperationsRobert P. Ragusa
Chief Financial Officer & Senior Vice PresidentSam A. Samad
Chief Technology Officer & Senior Vice PresidentMostafa Ronaghi

Company Highlights

Price Open$327.73
Previous Close$325.96
52 Week Range$263.30 - 380.76
Market Capitalization$47.7 B
Shares Outstanding147.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement01/29/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings49.58
Earnings per Share$5.49
Beta vs. S&P 500N/A
Revenue$3.3 B
Net Profit Margin28.14%
Return on Equity23.57%

Analyst Ratings as of 01/14/2020

Buy
11
Overweight
1
Hold
5
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset